Organon has not strayed from its women’s health path, but is entering into earlier deals and considering technologies beyond therapeutics, while advocating increased investment in the field.

Despite patient dissatisfaction, contraceptive options have made little advancement since the turn of the century – but a cohort of novel, non-hormonal products could see this all change.

Cidara gets $30m up front for US rights to the weekly echinocandin candidate for candidemia and invasive candidiasis. Takeda walks away from oncolytic virus candidate licensed from Turnstone.